Abstract
Purpose of Review
Pediatric central nervous system demyelinating diseases include multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and acute disseminated encephalomyelitis (ADEM). As diagnostic criteria become more inclusive, the risk of misdiagnosis of atypical demyelinating diseases of rheumatologic, infectious, and autoimmune etiology increases.
Recent Findings
We review mimics of multiple sclerosis, neuromyelitis optica spectrum disorder, and acute disseminated encephalomyelitis, including rheumatologic diseases: systemic lupus erythematosus and neuro-Behçet disease; infectious diseases: human immunodeficiency virus, progressive multifocal leukoencephalopathy, and subacute sclerosis panencephalitis; and autoimmune diseases including X-linked Charcot-Marie-Tooth disease, chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) and autoimmune glial fibrillary acidic protein (GFAP) encephalopathy.
Summary
Atypical demyelinating disease may mimic classic neuroinflammatory diseases of the central nervous system. Imaging may meet criteria for a diagnosis of multiple sclerosis, or patients may present with optic neuritis and transverse myelitis consistent with neuromyelitis optica spectrum or myelin oligodendrocyte glycoprotein (MOG) antibody disorders. Through careful history-taking and review of atypical MRI findings, we may avoid misdiagnosis and mistreatment.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Langer-Gould A, Zhang JL, Chung J, Yeung Y, Waubant E, Yao J. Incidence of acquired CNS demyelinating syndromes in a multiethnic cohort of children. Neurology. 2011;77:1143–8.
Belman AL, Krupp LB, Olsen CS, Rose JW, Aaen G, Benson L, et al. Network of Pediatric MS Centers. Characteristics of Children and Adolescents With Multiple Sclerosis. 2016 Pediatrics Jul;138(1). pii: e20160120. https://doi.org/10.1542/peds.2016-0120.
Barkhof F, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997;120(Pt 11):2059–69.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.
•• Wong YYM, et al. Real-world validation of the 2017 McDonald criteria for pediatric MS. Neurol Neuroimmunol. Neuroinflamm. 2019;6:e528 This study evaluates the specificity and sensitivity of the 2017 McDonald criteria for MS in children, particularly those under 12.
Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89.
Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology. 2016;86:245–52.
Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology. 2007;68:S7 LP–S12.
•• Hacohen Y, Banwell B. Treatment approaches for MOG-Ab-associated demyelination in children. Curr Treat Options Neurol. 2019;21:2 This review summarizes key publications reporting clinical presentation, antibody-detection, neuroimaging, and treatment of MOG-antibody associated demyelinating disease in children.
Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15:89–102.
Thulasirajah S, Pohl D, Davila-Acosta J, Venkateswaran S. Myelin oligodendrocyte glycoprotein-associated pediatric central nervous system demyelination: clinical course, Neuroimaging Findings, and Response to Therapy. Neuropediatrics. 2016;47:245–52.
Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler. 2016;22:174–84.
Ahn GY, Kim D, Won S, Song ST, Jeong HJ, Sohn IW, et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 2018;27:1338–47.
Li X, Xiang X, Sun J, Liu S, Liu Y, Feng L, et al. Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: a real world single center study. Mod Rheumatol. 2019:1–6. https://doi.org/10.1080/14397595.2019.1589912.
Lin Y-C, Wang A-G, Yen M-Y. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmol. 2009;87:204–10.
Hryb JP, et al. Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases. Spinal Cord Ser Cases. 2016;2:16005.
Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, Cacoub P, et al. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. Lupus. 2015;24:74–81.
Magro Checa C, Cohen D, Bollen EL, van Buchem M, Huizinga TW, Steup-Beekman GM. Demyelinating disease in SLE: is it multiple sclerosis or lupus? Best Pract Res Clin Rheumatol. 2013;27:405–24.
Dore-Duffy P, Donaldson JO, Rothman BL, Zurier RB. Antinuclear antibodies in multiple sclerosis. JAMA Neurol. 1982;39:504–6.
Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, Gruszka E, Korman L, Podemski R, et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus. 2012;21:412–20.
Merashli M, Alves JD, Gentile F, Ames PRJ. Relevance of antiphospholipid antibodies in multiple sclerosis: a systematic review and meta analysis. Semin Arthritis Rheum. 2017;46:810–8.
Probstel A-K, et al. Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. Rheumatology (Oxford). 2019;58:908–13.
Ozen S. Pediatric onset Behcet disease. Curr Opin Rheumatol. 2010;22:585–9.
Koné-Paut I. Behçet’s disease in children, an overview. Pediatr Rheumatol. 2016;14:10.
Akman-Demir G, Mutlu M, Kiyat-Atamer A, Shugaiv E, Kurtuncu M, Tugal-Tutkun I, et al. Behcet’s disease patients with multiple sclerosis-like features: discriminative value of Barkhof criteria. Clin Exp Rheumatol. 2015;33:S80–4.
Borhani Haghighi A, Sarhadi S, Farahangiz S. MRI findings of neuro-Behcet’s disease. Clin Rheumatol. 2011;30:765–70.
Farahangiz S, Sarhadi S, Safari A, Borhani-Haghighi A. Magnetic resonance imaging findings and outcome of neuro-Behcet’s disease: the predictive factors. Int J Rheum Dis. 2012;15:e142–9.
Fujimori J, et al. Two Japanese cases of anti-MOG antibody-associated encephalitis that mimicked neuro-Behcet’s disease. J Neuroimmunol. 2019;334:577002.
Perzynska-Mazan J, Maslinska M, Gasik R. Neurological manifestations of primary Sjogren’s syndrome. Reumatologia. 2018;56:99–105.
Birnbaum J, Atri NM, Baer AN, Cimbro R, Montagne J, Casciola-Rosen L. Relationship between neuromyelitis optica spectrum disorder and Sjogren’s syndrome: central nervous system extraglandular disease or unrelated, co-occurring autoimmunity? Arthritis Care Res (Hoboken). 2017;69:1069–75.
Jobling K, Ledingham D, Ng W-F, Guadagno J. Positive anti-MOG antibodies in a patient with Sjogren’s syndrome and transverse myelitis. Eur J Rheumatol. 2018;6:102–4.
Uriel A, et al. Tumefactive demyelination-an unusual neurological presentation of HIV. Clin Infect Dis. 2010;51:1217–20.
van Toorn R, Kritzinger F, Rabie H. Acute demyelinating encephalomyelitis (ADEM), cryptococcal reactivation and disseminated herpes simplex in an HIV infected child following HAART. Eur J Paediatr Neurol. 2005;9:355–9.
Tullu MS, Patil DP, Muranjan MN, Kher AS, Lahiri KR. Human immunodeficiency virus (HIV) infection in a child presenting as acute disseminated encephalomyelitis. J Child Neurol. 2011;26:99–102.
Patra KC, Shirolkar MS, Ghane VR. Acute disseminated encephalomyelitis: extremely rare presentation of pediatric human immunodeficiency virus infection. J Pediatr Neurosci. 2014;9:150–3.
Ferenczy MW, et al. Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev. 2012;25:471 LP–506.
Hennes EM, Kornek B, Huppke P, Reindl M, Rostasy K, Berger T. Age-dependent seroprevalence of JCV antibody in children. Neuropediatrics. 2016;47:112–4.
Huppke P, Hummel H, Ellenberger D, Pfeifenbring S, Stark W, Huppke B, et al. JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. Mult Scler. 2015;21:382–7.
Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology. 2013;80:1430–8.
Centers for Disease Control and Prevention. Measles cases and outbreaks. 2019. Available at: https://www.cdc.gov/measles/cases-outbreaks.html. Accessed 17th June 2019.
Mekki M, Eley B, Hardie D, Wilmshurst JM. Subacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions. Dev Med Child Neurol. 2019. https://doi.org/10.1111/dmcn.14166.
Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J. 2002;78:63–70.
Jafri SK, Kumar R, Ibrahim SH. Subacute sclerosing panencephalitis - current perspectives. Pediatr Heal Med Ther. 2018;9:67–71.
Dhawan SR, Kesavan S, Saini L, Singh P, Sahu JK, Sankhyan N. Diffuse white matter involvement in subacute sclerosing panencephalitis. Neuropediatrics. 2019;50:68–70.
Das B, Goyal MK, Modi M, Mehta S, Chakravarthi S, Lal V, et al. Atypical magnetic resonance imaging features in subacute sclerosing panencephalitis. Ann Indian Acad Neurol. 2016;19:275–6.
Tandra HV, Roy PS, Sharma R, Bhatia V, Saini AG. Subacute sclerosing panencephalitis presenting as choreoathetosis and basal ganglia hyperintensities. Neurohospitalist. 2019;9:26–9.
Raut TP, Singh MK, Garg RK, Naphade PU. Subacute sclerosing panencephalitis presenting as neuromyelitis optica. BMJ Case Rep. 2012 Dec 14;2012. pii: bcr2012006764. https://doi.org/10.1136/bcr-2012-006764.
Yilmaz C, Caksen H, Yilmaz N, Guven AS, Bayram I. Two cases of subacute sclerosing panencephalitis associated with brainstem involvement. J Trop Pediatr. 2007;53:280–3.
Markand ON, Panszi JG. The electroencephalogram in subacute sclerosing panencephalitis. Arch Neurol. 1975;32:719–26.
Dogulu CF, Ciger A, Saygi S, Renda Y, Yalaz K. Atypical EEG findings in subacute sclerosing panencephalitis. Clin Electroencephalogr. 1995;26:193–9.
Kwak M, Yeh HR, Yum MS, Kim HJ, You SJ, Ko TS. A long-term subacute sclerosing panencephalitis survivor treated with intraventricular interferon-alpha for 13 years. Korean J Pediatr. 2019;62:108–12.
Tomoda A, Shiraishi S, Hosoya M, Hamada A, Miike T. Combined treatment with interferon-alpha and ribavirin for subacute sclerosing panencephalitis. Pediatr Neurol. 2001;24:54–9.
Hara S, Kimura H, Hoshino Y, Hayashi N, Negoro T, Okumura A, et al. Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev. 2003;25:367–9.
Tatli B, Ekici B, Ozmen M. Current therapies and future perspectives in subacute sclerosing panencephalitis. Expert Rev Neurother. 2012;12:485–92.
Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol. 2007;36:1334–48.
Hanemann CO, Bergmann C, Senderek J, Zerres K, Sperfeld A-D. Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation. Arch Neurol. 2003;60:605–9.
Kim JK, Han S-A, Kim SJ. X-linked Charcot-Marie-Tooth disease with GJB1 mutation presenting as acute disseminated encephalomyelitis-like illness: a case report. Medicine (Baltimore). 2017;96:e9176.
Xie C, et al. CNS involvement in CMTX1 caused by a novel connexin 32 mutation: a 6-year follow-up in neuroimaging and nerve conduction. Neuro Sci. 2016;37:1063–70.
Zhao Y, et al. Transient, recurrent, white matter lesions in x-linked Charcot-Marie-tooth disease with novel mutation of gap junction protein beta 1 gene in China: a case report. BMC Neurol. 2014;14:156.
Koros C, Evangelopoulos M-E, Kilidireas C, Andreadou E. Central nervous system demyelination in a Charcot-Marie-Tooth type 1A patient. Case Rep Neurol Med. 2013;2013:243652.
Lee M, Park CH, Chung HK, Kim HJ, Choi Y, Yoo JH, et al. Cerebral white matter abnormalities in patients with charcot-marie-tooth disease. Ann Neurol. 2017;81:147–51.
Taieb G, Duflos C, Renard D, Audoin B, Kaphan E, Pelletier J, et al. Long-term outcomes of CLIPPERS (chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) in a consecutive series of 12 patients. Arch Neurol. 2012;69:847–55.
Tobin WO, Guo Y, Krecke KN, Parisi JE, Lucchinetti CF, Pittock SJ, et al. Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain. 2017;140:2415–25.
Nemani T, Udwadia-Hegde A, Keni Karnavat P, Kashikar R, Epari S. CLIPPERS spectrum disorder: a rare pediatric neuroinflammatory condition. Child Neurol Open. 2019;6:2329048X19831096.
Veerapandiyan A, Chaudhari A, Deo P, Ming X. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS): a pediatric case report with six year follow-up. Mult Scler Relat Disord. 2017;17:95–8.
Berzero G, Taieb G, Marignier R, Younan N, Savatovsky J, Leclercq D, et al. CLIPPERS mimickers: relapsing brainstem encephalitis associated with anti-MOG antibodies. Eur J Neurol. 2018;25:e16–7.
Symmonds M, Waters PJ, Küker W, Leite MI, Schulz UG. Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS. Neurology. 2015;84:1177–9.
Rempe T, et al. A case of CLIPPERS syndrome responsive to tocilizumab. Neurol Neuroimmunol. Neuroinflamm. 2019;6:e545.
Cipriani VP, Arndt N, Pytel P, Reder AT, Javed A. Effective treatment of CLIPPERS with long-term use of rituximab. Neurol Neuroimmunol Neuroinflamm. 2018;5:e448.
Shan F, Long Y, Qiu W. Autoimmune glial fibrillary acidic protein astrocytopathy: a review of the literature. Front Immunol. 2018;9:2802.
Dubey D, Hinson SR, Jolliffe EA, Zekeridou A, Flanagan EP, Pittock SJ, et al. Autoimmune GFAP astrocytopathy: prospective evaluation of 90 patients in 1 year. J Neuroimmunol. 2018;321:157–63.
Francisco C, Meddles K, Waubant E. Pediatric glial fibrillary acidic protein meningoencephalomyelitis: a case report and review of the literature. Mult Scler Relat Disord. 2019;29:148–52.
•• Fang B, McKeon A, Hinson SR, Kryzer TJ, Pittock SJ, Aksamit AJ, et al. Autoimmune glial fibrillary acidic protein astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol. 2016;73:1297–307 This is the first characterization of the clinical presentation, response to corticosteroids, and associated neoplasms in patients with seropositivity for GFAP immunoglobulin.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Regina M. Troxell and Alison Christy each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article is part of the Topical Collection on Demyelinating Disorders
Rights and permissions
About this article
Cite this article
Troxell, R.M., Christy, A. Atypical Pediatric Demyelinating Diseases of the Central Nervous System. Curr Neurol Neurosci Rep 19, 95 (2019). https://doi.org/10.1007/s11910-019-1015-y
Published:
DOI: https://doi.org/10.1007/s11910-019-1015-y